Get the Stockscreener App
2.11
4.09%
-0.09
After Hours:
2.14
0.03
+1.42%
Silexion Therapeutics Corp stock is traded at $2.11, with a volume of 32,683.
It is down -4.09% in the last 24 hours and down -30.13% over the past month.
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.
See More
Previous Close:
$2.20
Open:
$2.2
24h Volume:
32,683
Relative Volume:
0.49
Market Cap:
$6.60M
Revenue:
-
Net Income/Loss:
$-17.85M
P/E Ratio:
-0.0569
EPS:
-37.0644
Net Cash Flow:
$-13.02M
1W Performance:
+21.97%
1M Performance:
-30.13%
6M Performance:
-82.66%
1Y Performance:
-93.78%
1-Day Range:
$2.075
$2.30
1-Week Range:
$1.6495
$2.40
52-Week Range:
$1.6495
$51.75
Silexion Therapeutics Corp Stock (SLXN) Company Profile
Name
Silexion Therapeutics Corp
Sector
Industry
Phone
972-8-6286005
Address
12 ABBA HILLEL ROAD, RAMAT GAN
Compare SLXN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLXN
Silexion Therapeutics Corp
|
2.11 | 6.88M | 0 | -17.85M | -13.02M | -37.06 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Silexion Therapeutics Corp Stock (SLXN) Latest News
Silexion outlines 2026 plans after transformational 2025 progress - TipRanks
Silexion Therapeutics Corp Highlights 2025 Achievements and 2026 Milestones - TradingView — Track All Markets
Silexion Therapeutics' Cancer Drug to Enter Human Trials in Early 2026 - marketscreener.com
Silexion Therapeutics Reports Promising Preclinical Results for SIL204 in KRAS-Driven Cancers and Plans Phase 2/3 Trial Initiation for 2026 - Quiver Quantitative
Silexion Therapeutics Releases CEO Letter to Shareholders - GlobeNewswire
Merger Talk: Is Silexion Therapeutics Corp Equity Warrant stock trading at a premium valuation2025 Top Decliners & Daily Volume Surge Signals - moha.gov.vn
Can Silexion Therapeutics Corp Equity Warrant stock beat market expectations this quarterJuly 2025 Patterns & Fast Exit and Entry Trade Guides - Улправда
Can Silexion Therapeutics Corp Equity Warrant stock hit analyst price targetsJuly 2025 Retail & Free Technical Pattern Based Buy Signals - Улправда
Can Silexion Therapeutics Corp Equity Warrant stock hit record highs againJuly 2025 Weekly Recap & Daily Chart Pattern Signal Reports - Улправда
Will Silexion Therapeutics Corp Equity Warrant stock pay special dividendsTrade Exit Report & Weekly Top Performers Watchlists - DonanımHaber
How Silexion Therapeutics Corp stock compares to growth peersQuarterly Performance Summary & Free Real-Time Market Sentiment Alerts - DonanımHaber
Will Silexion Therapeutics Corp Equity Warrant stock reach Wall Street targetsJuly 2025 Technicals & Growth-Oriented Investment Plans - Улправда
Risk Analysis: Can Silexion Therapeutics Corp Equity Warrant stock hit analyst price targetsPortfolio Risk Report & High Conviction Trade Alerts - Улправда
Treasury Yields: How strong is Silexion Therapeutics Corp stock revenue growthWeekly Trade Report & AI Based Buy and Sell Signals - DonanımHaber
How strong is Silexion Therapeutics Corp stock revenue growthMarket Trend Summary & Real-Time Volume Spike Alerts - DonanımHaber
Silexion Therapeutics (NASDAQ:SLXN) Upgraded at Zacks Research - Defense World
Can Silexion Therapeutics Corp stock sustain free cash flow growth2025 Year in Review & Fast Exit/Entry Strategy Plans - Улправда
Gains Report: Will Silexion Therapeutics Corp Equity Warrant stock reach Wall Street targetsJuly 2025 Recap & AI Driven Stock Price Forecasts - Улправда
Stop Loss: Can Silexion Therapeutics Corp Equity Warrant stock hit record highs again - Улправда
Stock Recap: Will Silexion Therapeutics Corp Equity Warrant stock reach Wall Street targetsIPO Watch & Daily Profit Maximizing Trade Tips - Улправда
Silexion Therapeutics submits Phase 2/3 trial application - MSN
Silexion Therapeutics Submits Phase 2/3 Trial Application - TipRanks
Silexion submits Phase 2/3 trial application to Israel for SIL204 - TipRanks
Silexion Therapeutics Submits Phase 2/3 Trial Application for SIL204 - TradingView — Track All Markets
Silexion Therapeutics Advances Regulatory Submission for Phase 2/3 Trial of SIL204 in Pancreatic Cancer - Quiver Quantitative
Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for Sil204 in Locally Advanced Pancreatic Cancer - marketscreener.com
Silexion Therapeutics (NASDAQ:SLXN) Now Covered by Litchfield Hills Research - Defense World
Silexion Therapeutics Announces Submission of Phase 2/3 - GlobeNewswire
Silexion Therapeutics initiated with a buy at Litchfield Hills - MSN
Silexion Therapeutics initiated with a Buy at Litchfield Hills - TipRanks
Bearish Setup: Is Silexion Therapeutics Corp Equity Warrant stock recession proof2025 Momentum Check & AI Forecasted Entry/Exit Points - moha.gov.vn
Silexion Shares Decline After Update on German Regulatory Review - MSN
Silexion Therapeutics (SLXNW) Stock Analysis Report | Financials & Insights - Benzinga
How buybacks impact Silexion Therapeutics Corp stock valueProfit Target & Intraday High Probability Setup Alerts - Newser
Buy Recommendation for Silexion Therapeutics: Promising Developments and Market Potential in Pancreatic Cancer Treatment - TipRanks
Silexion Therapeutics drops 18%, prices $5M share offering - MSN
Silexion receives positive feedback from German Health Authority for SIL204 - TipRanks
Silexion Therapeutics (SLXN) Stock Analysis Report | Financials & Insights - Benzinga
Silexion stock falls after receiving German regulatory feedback By Investing.com - Investing.com Canada
Silexion stock falls after receiving German regulatory feedback - Investing.com
Silexion Therapeutics receives positive feedback from German health authority on design of phase 2/3 clinical trial - marketscreener.com
Silexion Therapeutics Gains Positive Feedback for SIL204 Trial - TipRanks
Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer - The Manila Times
How Silexion Therapeutics Corp Equity Warrant stock reacts to Fed rate cuts2025 Buyback Activity & Weekly Stock Breakout Alerts - Newser
Aug Mood: Can Silexion Therapeutics Corp Equity Warrant stock sustain free cash flow growthJuly 2025 Catalysts & Consistent Profit Trade Alerts - moha.gov.vn
SLXNSilexion Therapeutics Corp Latest Stock News & Market Updates - Stock Titan
Its Stock Has Paid Off Big Time For Silexion Therapeutics Corp - setenews.com
Silexion Therapeutics completes toxicology studies for SIL204 - MSN
Silexion stock jumps after toxicology studies show no systemic toxicity - MSN
Silexion Completes Toxicology Studies For SIL204; Phase 2/3 Pancreatic Cancer Trial To Begin In Q2 - Nasdaq
Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference - marketscreener.com
Silexion Therapeutics Corp Stock (SLXN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):